|
|
|
|
| LEADER |
01569nam a22003135i 4500 |
| 001 |
000289237 |
| 005 |
20210526143719.0 |
| 007 |
cr nn 008mamaa |
| 008 |
110506s2011 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781441984593
|
| 024 |
7 |
|
|a 10.1007/978-1-4419-8459-3
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a New Agents for the Treatment of Acute Lymphoblastic Leukemia /
|c edited by Vaskar Saha, Pamela Kearns.
|
| 250 |
|
|
|a 1st ed. 2011.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2011.
|
| 300 |
|
|
|a XVIII, 338 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a The need for new agents -- Identifying pre-clinical agents -- Pre-clinical evaluation -- Design of early phase trials -- Strategies for trial design and analyses -- Overview on Molecular and Animal models of ALL -- Apoptosis, BCL2 -- Targeting Stem Cells -- Nucleoside Analogues -- Flt3 Inhibitors -- Tyrosine Kinase Inhibitors -- Monoclonal Antibodies -- Proteasome inhibitors -- Targeting epigenetic pathways in ALL.- Incorporating new therapies in frontline protocols.-.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Saha, Vaskar.
|e editor.
|
| 700 |
1 |
|
|a Kearns, Pamela.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|